Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria

Jonathan Graham, Doreen McBride, Donald Stull, Anna Halliday (), Stamatia Theodora Alexopoulos, Maria-Magdalena Balp, Matthew Griffiths, Ion Agirrezabal, Torsten Zuberbier and Alan Brennan
Additional contact information
Jonathan Graham: RTI Health Solutions
Doreen McBride: RTI Health Solutions
Donald Stull: RTI Health Solutions
Anna Halliday: Novartis Pharmaceuticals UK Limited
Stamatia Theodora Alexopoulos: Novartis Pharmaceuticals UK Limited
Maria-Magdalena Balp: Novartis Pharma AG
Matthew Griffiths: Costello Medical Consulting Ltd
Ion Agirrezabal: Costello Medical Consulting Ltd
Torsten Zuberbier: Charité-University Hospital Berlin
Alan Brennan: University of Sheffield

PharmacoEconomics, 2016, vol. 34, issue 8, No 8, 815-827

Abstract: Abstract Background Chronic spontaneous urticaria (CSU) negatively impacts patient quality of life and productivity and is associated with considerable indirect costs to society. Objective The aim of this study was to assess the cost utility of add-on omalizumab treatment compared with standard of care (SOC) in moderate or severe CSU patients with inadequate response to SOC, from the UK societal perspective. Methods A Markov model was developed, consisting of health states based on Urticaria Activity Score over 7 days (UAS7) and additional states for relapse, spontaneous remission and death. Model cycle length was 4 weeks, and total model time horizon was 20 years in the base case. The model considered early discontinuation of non-responders (response: UAS7 ≤6) and retreatment upon relapse (relapse: UAS7 ≥16) for responders. Clinical and cost inputs were derived from omalizumab trials and published sources, and cost utility was expressed as incremental cost-effectiveness ratios (ICERs). Scenario analyses included no early discontinuation of non-responders and an altered definition of response (UAS7

Date: 2016
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-016-0412-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:34:y:2016:i:8:d:10.1007_s40273-016-0412-1

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-016-0412-1

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().